Phase 2 Clinical Trial Initiated for CD22 CAR T Cells to Prevent Relapse After CD19 Therapy
Background and Rationale
CD19 CAR T-cell therapy has demonstrated substantial efficacy in patients with acute lymphoblastic leukemia, yet approximately 50% of patients experience relapse within one year. Consequently, an additional immune attack targeting CD22, a distinct antigen from CD19, is being pursued.
Study Objectives and Design
This Phase 2 trial enrolls patients aged 3 to 65 who have achieved complete remission following CD19 CAR T therapy, to assess the durability of remission with CD22 CAR T-cell treatment. Participants will undergo leukapheresis, cellular modification, and conditioning before receiving an infusion of CD22 CAR T cells. Relapse rates and safety will be monitored over a two‑year follow‑up period.
Differentiation and Expected Benefits
Targeting CD22 enables recognition of malignant cells even when resistance to CD19 or antigen loss occurs, offering a complementary effect to existing CD19 CAR T therapy. Sequential utilization of both targets may extend the duration of remission and reduce the risk of relapse.
Clinical and Industry Impact
If the study yields positive outcomes, the scope of CAR T therapy could broaden, opening new avenues to overcome resistance to existing treatments. Investors and biopharma companies are expected to increase interest in CD22‑based CAR T platforms, driving pipeline expansion and greater partnership opportunities.
CD22 CAR T cells address the relapse limitation of CD19 therapy, offering substantial market growth potential and making them highly attractive to investors. Consequently, demand for talent in CAR T platform development and manufacturing is expected to rise.
Source: ClinicalTrials.gov (api_ct)